Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05028764 · ClinicalTrials.gov registry record
Determine Range of Tissue Frataxin Concentrations and Other Potential Biomarkers
A clinical trial, sponsored by Larimar Therapeutics.
- Completed
- Registry status
- 60
- Enrollment target
NCT05028764: Completed study, sponsored by Larimar Therapeutics.
NCT05028764 is a clinical trial that has completed, run by Larimar Therapeutics. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05028764 has completed, sponsored by Larimar Therapeutics.
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
Study Summary
To examine range of tissue frataxin (FXN) concentrations, specific ribonucleic acids, other proteins and specialized lipids in the buccal cells, blood, and skin cells of normal healthy volunteers without Friedreich's ataxia (FRDA).
Primary Outcome
Range of tissue frataxin levels in buccal cells, blood and skin cells
Interventions
- DIAGNOSTIC_TEST Buccal Swabs, Blood Draws and Skin Punch Biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-08-04 |
| Est. Completion | 2022-02-04 |
What the finished NCT05028764 record still lists
NCT05028764 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Buccal Swabs, Blood Draws and Skin Punch Biopsy is the first listed.
NCT05028764 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05028764 about?
NCT05028764 is a clinical study titled "Determine Range of Tissue Frataxin Concentrations and Other Potential Biomarkers". To examine range of tissue frataxin (FXN) concentrations, specific ribonucleic acids, other proteins and specialized lipids in the buccal cells, blood, and skin cells of normal healthy volunteers without Friedreich's ataxia (FRDA).
What is the current status of trial NCT05028764?
This trial is currently completed. The enrollment target is 60 participants. The study started on 2021-08-04. Estimated completion is 2022-02-04.
What interventions are being tested in trial NCT05028764?
The interventions under investigation include: Buccal Swabs, Blood Draws and Skin Punch Biopsy (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05028764?
This trial is sponsored by Larimar Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI